ADPT
NCCN Guidelines Name ADAPTIVE BIOTECHNOLOGIES' clonoSEQ for Myeloma MRD Testing
Updated NCCN myeloma guidelines add a dedicated MRD testing page and name clonoSEQ as the only assay specifically cited, with 10-6 sensitivity preferred.
ADPT
Market-moving news on Adaptive Biotechnologies (NASDAQ: ADPT): filings, earnings, deals and other events, from REDFILED.